

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**RESIGNATION OF DIRECTOR AND CHIEF FINANCIAL OFFICER
AND
APPOINTMENT OF DIRECTOR AND CHIEF FINANCIAL OFFICER**

Resignation of Director and Chief Financial Officer

The board of directors (the “**Board**”) of Sisram Medical Ltd (the “**Company**”) hereby announced that Mr. Jianping HUA has tendered his resignation from the positions of executive director and chief financial officer of the Company with effect from 17 January 2019 due to his decision to pursue his personal development.

Mr. Jianping HUA has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board hereby expresses its gratitude to Mr. Jianping HUA for his valuable contribution to the Company during his term of office.

Appointment of Director and Chief Financial Officer

The Board also announced that, with effect from 17 January 2019, Mr. Guojun BU (“**Mr. Bu**”) has been appointed as an executive director and the chief financial officer of the Company.

Mr. Bu, aged 43, has more than 20 years of financial management experience in medical and healthcare industry, in particular in finance operation, financing and investment activities. Mr. Bu has been the vice president of Chindex Medical Limited (“**CML**”), a controlling shareholder of the Company and a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), and the vice president of the Medical Technology Division of Fosun Pharma, in charge of finance operation and financing and investment activities for medical device business, since January 2017 and January 2019, respectively. He has also acted as the general manager of the finance department of CML from January 2011 to December 2016. Mr. Bu worked with Chindex International, Inc. from January 1997 to December 2010, where he held a number of positions comprising finance manager, senior finance manager, assistant finance director and finance director of China region. Mr. Bu graduated in July 1996 from Beijing University of Technology (the PRC) majoring in Economic Information Management and obtained a master’s degree in Computer Science and Technology from Beijing University of Technology in July 2010 and an EMBA degree from Rutgers, the State University of New Jersey (United States) in November 2011, respectively.

Save as disclosed above, Mr. Bu did not hold any directorship in listed public companies in the three years preceding the date of this announcement, nor does he has any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company.

As at the date of this announcement, Mr. Bu does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Bu has entered into a letter of appointment with the Company for a period commencing from 17 January 2019 and ending on 30 August 2020 in accordance with the articles of association of the Company. Pursuant to the articles of association of the Company, Mr. Bu will hold office as executive director of the Company until the forthcoming annual general meeting of the Company and will then stand for re-election at that meeting. Mr. Bu will not receive any emolument from the Company for acting as director and chief financial officer of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders in connection with Mr. Bu's appointments and there is no other information that should be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend their warm welcome to Mr. Bu in joining the Board.

On Behalf of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, 17 January 2019

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*